Alector, Inc. filings document a Nasdaq-listed biotechnology issuer developing therapies for neurodegenerative diseases and reporting progress across the Alector Brain Carrier (ABC) platform. Its 8-K reports include operating and financial results, clinical and portfolio updates, material agreements, and officer appointments.
Regulatory documents also cover the company’s common stock, shelf registration statement and at-the-market equity sales agreement, along with governance matters in proxy materials such as board elections, executive compensation and shareholder voting items. Clinical disclosures address programs in Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia and related neurological disorders, while event filings frame capital resources, platform development, trial outcomes and pipeline changes.
Alector Inc: The Vanguard Group filed Amendment No. 5 to a Schedule 13G reporting 0% beneficial ownership of Common Stock as of 03/13/2026.
The filing states 01/12/2026 internal realignment caused certain Vanguard subsidiaries to report disaggregated holdings and that Vanguard no longer is deemed to beneficially own securities held by those entities. The filing is signed by Ashley Grim on 03/26/2026.
Rosenthal Arnon reported acquisition or exercise transactions in this Form 4 filing.
Alector, Inc. chief executive officer Arnon Rosenthal reported an equity compensation grant of restricted stock units representing 116,246 shares of common stock on March 13, 2026. The RSUs were granted at no cash cost and will vest in two equal installments: one half on September 1, 2026 and one half on March 1, 2027.
Following the award, Rosenthal directly owns 2,454,422 common shares. He also reports additional indirect holdings through family trusts, including shares held by The Rosenthal Family Revocable Trust and by three 2007 trusts for family members.
Alector, Inc. reported that its CFO & Chief Business Officer, Neil Lindsay Berkley, received an equity award of 54,600 shares of Common Stock in the form of restricted stock units. These RSUs were granted at no cash cost and increase his direct holdings to 399,260 shares.
The award vests over time: one half of the RSUs will vest on September 1, 2026, and the remaining half will vest on March 1, 2027. Vesting means the units convert into unrestricted shares if the applicable service-based conditions are satisfied.
Alector, Inc. principal accounting officer Grace Wong-Sarad reported an open-market sale of 1,000 shares of common stock at $2.65 per share. The transaction took place on March 10, 2026, and she now holds 106,465 shares directly. The filing notes the sale was made under a Rule 10b5-1 trading plan adopted on September 5, 2025, indicating it was pre-scheduled rather than a discretionary trade.
Alector, Inc. has filed a shelf registration to offer up to $400,000,000 of securities, including common stock, preferred stock, debt securities, warrants, purchase contracts and units, under a prospectus dated March 12, 2026.
The prospectus is a shelf registration statement allowing multiple offerings from time to time and states that the registration includes $308,196,683.14 of unsold securities carried forward pursuant to Rule 415(a)(6) from the prior registration (File No. 333-270126). The offering will be made by prospectus supplements that set specific terms, methods of sale, and use of proceeds.
ALEC: Form 144 notice of proposed sale by Grace Wong-Sarad. The filing lists recent open-market dispositions: 3,367 Common shares sold on 03/03/2026 for $7,012.11; 8,071 Common shares sold on 03/02/2026 for $17,137.75; and 4,079 Common shares sold on 02/26/2026 for $10,197.50. The filing also lists 1,000 Restricted Stock units tied to an 03/01/2025 grant that are indicated as securities to be sold.
Alector, Inc. reported that Principal Accounting Officer Grace Wong-Sarad sold 3,367 shares of common stock in an open-market transaction. The sale occurred on March 3, 2026 at a weighted average price of $2.0826 per share, with individual sale prices ranging from $2.06 to $2.12. These transactions were made under a pre-established Rule 10b5-1 trading plan adopted on September 5, 2025. After this sale, Wong-Sarad directly owned 107,465 shares of Alector common stock.
ALEC filed a Form 144 reporting the proposed sale of 3,367 restricted common shares through Morgan Stanley Smith Barney LLC. The filing lists recent dispositions by Grace Wong-Sarad: 8,071 shares on 03/02/2026 with 17137.75, 4,079 shares on 02/26/2026 with 10197.50, and 4,753 shares on 12/05/2025 with 5751.13.
Alector, Inc. Principal Accounting Officer Grace Wong-Sarad reported an open-market sale of 8,071 shares of common stock. The weighted average sale price was $2.1234 per share, with individual trades executed between $2.04 and $2.37 per share.
According to the disclosure, the shares were sold to satisfy the reporting person's tax obligations arising from the vesting of restricted stock units. After this transaction, the officer directly owned 110,832 shares of Alector common stock.
Alector, Inc. Chief Executive Officer Arnon Rosenthal reported an open-market sale of 81,864 shares of common stock on March 2, 2026 at a weighted average price of $2.1233 per share. According to the footnotes, the shares were sold to satisfy his tax obligations arising from the vesting of restricted stock units.
After this sale, Rosenthal directly owns 2,338,176 shares of Alector common stock. He also has indirect holdings through family trusts, including 1,972,875 shares held by The Rosenthal Family Revocable Trust and 652,500 shares each held by the Adi Rosenthal 2007 Trust, the Noam Rosenthal 2007 Trust, and the Shani Rosenthal 2007 Trust, for which he serves as trustee.